| The Warburg Effect in Diabetic Kidney Disease |
20 |
| Phenotyping of Acute Kidney Injury: Beyond Serum Creatinine |
19 |
| Epidemiology of IgA Nephropathy: A Global Perspective |
19 |
| Kidney-Immune System Crosstalk in AKI |
18 |
| The Role of Peroxisome Proliferator-Activated Receptor gamma Coactivator 1 alpha (PGC-1 alpha) in Kidney Disease |
15 |
| The Warburg Effect, Lactate, and Nearly a Century of Trying to Cure Cancer |
15 |
| Updates on the Mechanisms and the Care of Cardiovascular Calcification in Chronic Kidney Disease |
12 |
| Gut Microbiota-Kidney Cross-Talk in Acute Kidney Injury |
12 |
| Aberrant Glycosylation of the IgA1 Molecule in IgA Nephropathy |
11 |
| The Gut-Renal Connection in IgA Nephropathy |
11 |
| Cardiovascular Disease and Diabetic Kidney Disease |
11 |
| HIF Activation Against CVD in CKD: Novel Treatment Opportunities |
11 |
| Heart Failure in End-Stage Kidney Disease: Pathophysiology, Diagnosis, and Therapeutic Strategies |
10 |
| Using Technology to Inform and Deliver Precise Personalized Care to Patients With End-Stage Kidney Disease |
10 |
| Fibroblast Growth Factor 23 and Klotho in AKI |
10 |
| Metabolomics and Metabolic Reprogramming in Kidney Cancer |
9 |
| Cellular and Molecular Mechanisms of Kidney Toxicity |
8 |
| The Role of Risk Prediction Models in Prevention and Management of AKI |
8 |
| Cardiovascular Disease After Kidney Transplant |
8 |
| Cardiovascular Disease Risk in Children With Kidney Disease |
8 |
| Proteomics and Metabolomics for AKI Diagnosis |
8 |
| Bringing Renal Biopsy Interpretation Into the Molecular Age With Single-Cell RNA Sequencing |
8 |
| Epidemiology, Pathophysiology, and Management of Hepatorenal Syndrome |
8 |
| Iron Homeostasis in Healthy Kidney and its Role in Acute Kidney Injury |
7 |
| Pathologic Perspectives on Acute Tubular Injury Assessment in the Kidney Biopsy |
7 |
| Update on Chronic Kidney Disease Mineral and Bone Disorder in Cardiovascular Disease |
7 |
| Cardiovascular Disease in Children and Adolescents With Chronic Kidney Disease |
7 |
| Environmental and Genetic Factors Influencing Kidney Toxicity |
7 |
| Personalized Anemia Management and Precision Medicine in ESA and Iron Pharmacology in End-Stage Kidney Disease |
7 |
| Blood Purification Techniques for Sepsis and Septic AKI |
7 |
| Mitochondrial Dysfunction and Signaling in Diabetic Kidney Disease: Oxidative Stress and Beyond |
7 |
| Molecular Pathophysiology of Acid-Base Disorders |
6 |
| Pathophysiological Role of Organelle Stress/Crosstalk in AKI-to-CKD Transition |
6 |
| Histologic Classification of IgA Nephropathy: Past, Present, and Future |
6 |
| Precision Medicine in the Transition to Dialysis and Personalized Renal Replacement Therapy |
6 |
| Precision Medicine for Acute Kidney Injury (AKI): Redefining AKI by Agnostic Kidney Tissue Interrogation and Genetics |
6 |
| Pulmonary Consequences of Acute Kidney Injury |
6 |
| Cardiorenal Syndrome in Acute Kidney Injury |
6 |
| AKI and the Neuroimmune Axis |
6 |
| Environmental and Occupational Exposures in Kidney Disease |
6 |
| Balkan Endemic Nephropathy and the Causative Role of Aristolochic Acid |
6 |
| Genetic and Developmental Factors in Chronic Kidney Disease Hotspots |
5 |
| Mesoamerican Nephropathy |
5 |
| Role of the Spleen Tyrosine Kinase Pathway in Driving Inflammation in IgA Nephropathy |
5 |
| Biomarkers and Precision Medicine in IgA Nephropathy |
5 |
| Emerging In Vitro Systems to Screen and Predict Drug-Induced Kidney Toxicity |
5 |
| Targeting Glucosylceramide Synthesis in the Treatment of Rare and Common Renal Disease |
5 |
| Cardiovascular Risk Prediction in CKD |
5 |
| Dialysis Patient-Centeredness and Precision Medicine: Focus on Incremental Home Hemodialysis and Preserving Residual Kidney Function |
5 |
| Emerging Features of Ammonia Metabolism and Transport in Acid-Base Balance |
5 |
